Acute graft-versus-host disease
F Malard, E Holler, BM Sandmaier, H Huang… - Nature Reviews …, 2023 - nature.com
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
[HTML][HTML] First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
PJ Martin, JD Rizzo, JR Wingard, K Ballen… - Biology of Blood and …, 2012 - Elsevier
Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many
patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic …
patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic …
EBMT− NIH− CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Several international recommendations address the assessment of graft-versus-host
disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by …
disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by …
[HTML][HTML] Intestinal Blautia is associated with reduced death from graft-versus-host disease
The relationship between intestinal microbiota composition and acute graft-versus-host
disease (GVHD) after allogeneic blood/marrow transplantation (allo-BMT) is not well …
disease (GVHD) after allogeneic blood/marrow transplantation (allo-BMT) is not well …
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice
Intestinal bacteria may modulate the risk of infection and graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients …
after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients …
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
M Jagasia, M Arora, MED Flowers… - Blood, The Journal …, 2012 - ashpublications.org
Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were
evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from …
evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from …
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus …
MED Flowers, Y Inamoto, PA Carpenter… - Blood, The Journal …, 2011 - ashpublications.org
Risk factors for grades 2-4 acute graft-versus-host disease (GVHD) and for chronic GVHD as
defined by National Institutes of Health consensus criteria were evaluated and compared in …
defined by National Institutes of Health consensus criteria were evaluated and compared in …
Review of graft-versus-host disease
V Ramachandran, SS Kolli, LC Strowd - Dermatologic Clinics, 2019 - derm.theclinics.com
Methods A PubMed search was conducted using the search terms “graft versus host
disease,”“acute GVHD,”“chronic GVHD,”“pathophysiology,”“diagnosis,” and “treatment.” …
disease,”“acute GVHD,”“chronic GVHD,”“pathophysiology,”“diagnosis,” and “treatment.” …
[HTML][HTML] A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease
P Kebriaei, J Hayes, A Daly, J Uberti, DI Marks… - Biology of Blood and …, 2020 - Elsevier
Uncontrolled studies have suggested that bone marrow-derived mesenchymal stem cells
(MSCs) may be effective against acute graft-versus-host disease (aGVHD). We conducted a …
(MSCs) may be effective against acute graft-versus-host disease (aGVHD). We conducted a …
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
H Major-Monfried, AS Renteria… - Blood, The Journal …, 2018 - ashpublications.org
Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid
immunosuppression. Clinical response after 1 week of therapy often guides further treatment …
immunosuppression. Clinical response after 1 week of therapy often guides further treatment …